

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Brilliant Violet 570(TM) anti-mouse/human CD44

RRID:AB_10900641

Type: Antibody

Proper Citation

BioLegend Cat# 103037, RRID:AB_10900641

Antibody Information

URL: http://antibodyregistry.org/AB_10900641

Proper Citation: BioLegend Cat# 103037, RRID:AB_10900641

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 570(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_10900641

Vendor: BioLegend

Catalog Number: 103037

Record Creation Time: 20250820T045701+0000

Record Last Update: 20250820T202231+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 570(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 570(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. Cancer immunology research, 14(1), 122.

Corgnac S, et al. (2025) TGF- β and IL-12 conversely orchestrate the formation of CD103+ CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine. iScience, 28(8), 113147.

Coulibaly ASK, et al. (2025) Id2 levels determine the development of effector vs. exhausted tissue-resident memory CD8+ T cells during CNS chronic infection. Cell reports, 44(6), 115861.

Wang Y, et al. (2025) Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting. Cell reports. Medicine, 6(8), 102250.

Ravi VR, et al. (2025) Lung CD4+ resident memory T cells use airway secretory cells to stimulate and regulate onset of allergic airway neutrophilic disease. Cell reports, 44(3), 115294.

Bachem A, et al. (2025) Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8+ T cell immunity against melanoma. Immunity, 58(11), 2799.

Cheng JN, et al. (2025) Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. Cancer cell, 43(6), 1093.

Ross RB, et al. (2024) PPAR γ Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(9), 1916.

Seldeslachts L, et al. (2024) Damping excessive viral-induced IFN- γ rescues the impaired anti-Aspergillus host immune response in influenza-associated pulmonary aspergillosis. EBioMedicine, 108, 105347.

Gadwa J, et al. (2023) Selective targeting of IL2R α combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell reports. Medicine, 4(8), 101150.

Meiser P, et al. (2023) A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. *Cancer cell*, 41(8), 1498.

Piper M, et al. (2023) Simultaneous targeting of PD-1 and IL-2R?? with radiation therapy inhibits pancreatic cancer growth and metastasis. *Cancer cell*, 41(5), 950.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. *Cell reports*, 41(3), 111478.

Hua Y, et al. (2022) Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. *Cancer cell*, 40(12), 1600.

Scheyltjens I, et al. (2022) Single-cell RNA and protein profiling of immune cells from the mouse brain and its border tissues. *Nature protocols*, 17(10), 2354.